Theratechnologies disclosed the study design and baseline characteristics of participants in the Prospective Observational Study of Multidrug-Resistant Patient Outcomes with and without Ibalizumab in a Real-World Setting: United States, PROMISE-US. The study seeks to fill a critical gap in long-term clinical outcomes for heavily treatment-experienced, HTE, people with HIV, PWH, while illuminating factors contributing to maintenance of virologic control. The study’s primary objective is to evaluate the long-term efficacy and durability of ibalizumab in combination with other antiretroviral therapies by comparing the clinical outcomes of patients receiving ibalizumab versus matched patients not receiving ibalizumab.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THTX:
- Theratechnologies downgraded to Hold from Buy at JonesResearch
- Delta reports mixed Q3, Domino’s reports earnings beat: Morning Buzz
- Morning Movers: GXO Logistics gains following report of potential sale
- Theratechnologies Celebrates Strong Q3 Results and Raised Outlook
- Theratechnologies reports Q3 EPS 6c, consensus 3c